Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07298447 · ClinicalTrials.gov registry record · Phase 3
Donidalorsen Treatment in Children With Hereditary Angioedema
A Phase 3 study of Hereditary Angioedema (HAE), sponsored by Ionis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 20
- Enrollment target
- 3
- Study locations
NCT07298447: Recruiting Phase 3 study of Hereditary Angioedema (HAE), sponsored by Ionis Pharmaceuticals.
NCT07298447 is a Phase 3 study of Hereditary Angioedema (HAE) that is actively recruiting participants, run by Ionis Pharmaceuticals. The registered enrollment target is 20 participants, below the 65-participant average among 7 other Hereditary Angioedema (HAE) trials with a reported enrollment target (69% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07298447, a Phase 3 study of Hereditary Angioedema (HAE), is actively recruiting participants, sponsored by Ionis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 20 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of donidalorsen in pediatric participants with hereditary angioedema (HAE) Type I (HAE-1) or Type II (HAE-2).
Conditions Studied
Interventions
- DRUG Donidalorsen
Study Locations (3)
California
- Ionis Investigative Site - Santa Monica
Missouri
- Ionis Investigative Site - St Louis
Ohio
- Ionis Investigative Site - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-07 |
| Est. Completion | 2029-06 |
| Phase | Phase 3 |
What NCT07298447 shows while recruiting
NCT07298447 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 65-participant average among 7 other Hereditary Angioedema (HAE) trials with a reported enrollment target (69% lower).
The record links to 1 condition, with Hereditary Angioedema (HAE) appearing as the primary indexed condition, and to 1 intervention - of which Donidalorsen is the first listed.
NCT07298447 reports a single indexed study location in California, Missouri, Ohio.
Frequently Asked Questions
What is clinical trial NCT07298447 about?
NCT07298447 is a clinical study titled "Donidalorsen Treatment in Children With Hereditary Angioedema". The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of donidalorsen in pediatric participants with hereditary angioedema (HAE) Type I (HAE-1) or Type II (HAE-2).
What is the current status of trial NCT07298447?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 20 participants. The study started on 2026-07. Estimated completion is 2029-06.
What conditions does trial NCT07298447 study?
This clinical trial studies the following conditions: Hereditary Angioedema (HAE).
What interventions are being tested in trial NCT07298447?
The interventions under investigation include: Donidalorsen (DRUG).
Who is sponsoring clinical trial NCT07298447?
This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07298447 being conducted?
This trial has 3 study locations across California, Missouri, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hereditary Angioedema (HAE)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Navenibart in Participants With Hereditary Angioedema
RECRUITING · Phase 3
-
Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
RECRUITING · Phase 3
-
Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
ACTIVE NOT RECRUITING · Phase 3
-
Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema
COMPLETED · Phase 3
-
Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients
RECRUITING · Phase 1
-
A Phase 2 in Adult Subjects With Hereditary Angioedema
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia